Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Aβ(1-42)-induced brain inflammation and neuronal damage in the rat

International Journal of Immunopathology and Pharmacology

Volumn 17, Issue 3, 2004, Pages 317-330

  Prosperi, C ^a   Scali, C ^a   Barba, M ^b   Bellucci, A ^a   Giovannini, M G ^a   Pepeu, G ^a   Casamenti, Fiorella ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Nicox Research Institute   (Italy)

Author keywords

Alzheimer's disease; Animal model; Anti inflammatory drugs; Glia reaction; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ANTIINFLAMMATORY AGENT; CHOLINE ACETYLTRANSFERASE; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; FLURBIPROFEN DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE 5 NITRATE; MITOGEN ACTIVATED PROTEIN KINASE; NCX 2216; NITRIC OXIDE; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; ATTENUATION; CELL LOSS; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; ENCEPHALITIS; EPIDEMIOLOGICAL DATA; GLIA CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INJECTION SITE; MALE; MICRODIALYSIS; MICROGLIA; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; OLIVARY NUCLEUS; PATHOGENESIS; PRIORITY JOURNAL; RAT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 7244223227     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200401700312     Document Type: Article

References (38)

1. Etminan M., S. Gill and A. Samii. 2003. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327:128.
2. Vane J.R., Y.S. Bakle and R.M. Botting. 1998. Cyclooxygenase 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:97.
3. FitzGerald G.A. and C. Patrono. 2001. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J Med. 345:433.
4. Del Soldato P., R. Sorrentino and A. Pinto. 1999. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 20:319.
5. Burgaud J.L., J.P. Riffaud and P. Del Soldato. 2002. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr. Pharm. Des. 8:201.
6. Wallace J.L., B. Reuter, C. Cicala, W. McKnight, M.B. Grisham and G. Cirino. 1994. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterol. 107:173.
7. Fiorucci S., L. Santucci, B. Federici, E. Antonelli, E. Distrutti, O. Morelli, G.D. Renzo, G. Coata, G. Cirino, P.D. Soldato and A. Morelli. 1999. Nitric oxide-releasing NSAIDs inhibit interleukin-Ibeta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha. Aliment. Pharmacol. Ther. 13:421.
8. Williams J.L., S. Borgo, I. Hasan, E. Castillo, F. Traganos and B. Rigas. 2001. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res. 61:3285.
9. MacNaughton W.K., G. Cirino and J.L. Wallace. 1989. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sciences 45:1869.
10. Kitagawa H., F. Takeda and H. Kohei. 1990. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCL in rats. Pharmacol. Exp. Therap. 253:1133.
11. Santucci L., S. Fiorucci, L. Patoia, F.M. Di Matteo, P.M. Brunori and A. Morelli. 1995. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig. Dis. Sci. 40:2074.
12. Loscalzo J. 2001. Inducible NO synthesis in the vasculature: molecular context defines physiological response. Arterioscler. Thromb. Vasc. Biol. 21:1259.
13. Akiyama H., S. Barger, S. Barnum, B. Bradt, J. Bauer, G.M. Cole, N.R. Cooper, P. Eikelenboom, M. Emmerling, B.L. Fiebich, C.E. Finch, S. Frautschy, W.S. Griffin, H. Hampel, M. Hull, G. Landreth, L. Lue, R. Mrak, I.R. Mackenzie, P.L. McGeer, M.K. O'Banion, J. Pachter, G. Pasinetti, C. Plata-Salaman, J. Rogers, R. Rydel, Y. Shen, W. Streit, R. Strohmeyer, I. Tooyoma, F.L. van Muiswinkel, R. Veerhuis, D. Walker, S. Webster, B. Wegrzyniak, G. Wenk and T. Wyss-Coray. 2000. Inflammation and Alzheimer's disease. Neurobiol. Aging 21:383.
14. McGeer E.G. and P.L. McGeer. 1999. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharm. Des 5:821.
15. Pasinetti G.M. and P.S. Aisen. 1998. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 87:319.
16. Ho L., C. Pieroni, D. Winger, D.P. Purohit, P.S. Aisen and G.M. Pasinetti. 1999. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J. Neurosci. Res. 57:295.
17. Aisen P.S., K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas and L.J. Thai. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819.
18. Prosperi C., C. Scali, G. Pepeu and F. Casamenti. 2001. NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain. Jpn. J. Pharmacol. 86:230.
19. Wenk G.L., K. McGann, A. Mencarelli, B. Hauss-Wegrzyniak, P. Del Soldato and S. Fiorucci. 2000. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur. J. Pharmacol. 402:77.
20. Jantzen P.T., K.E. Connor, G. DiCarlo, G.L. Wenk, J.L. Wallace, A.M. Rojiani, D. Coppola, D. Morgan and M.N. Gordon. 2002. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22:2246.
21. Casamenti F., C. Prosperi, C. Scali, L. Giovannelli and G. Pepeu. 1998. Morphological, biochemical and behavioural changes induced by neurotoxic and inflammatory insults to the nucleus basalis. Int. J. Develop. Neurosc. 16:705.
22. Giovannini M.G., C. Scali, C. Prosperi, A. Bellucci, M.G. Vannucchi, S. Rosi, G. Pepeu and F. Casamenti. 2002. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol. Dis. 11:257.
23. Hevel J.M. and M.A. Marietta. 1994. Nitric-oxide synthase assays. Methods Enzymol. 233:250.
24. Espey M.G., K.M. Miranda, R.M. Pluta and D.A. Wink. 2000. Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals. J. Biol. Chem. 275:11341.
25. Aldini G., M. Carini, M. Orioli, R.M. Facino and G.L. Wenk. 2002. Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: a LC-MS study. Life Sci. 71:1487.
26. Benveniste H. 1989. Brain microdialysis. Journal of Neurochemistry 52:1667.
27. Vallebuona F. and M. Raiteri. 1994. Extracellular cGMP in the hippocampus of freely moving rats as an index of nitric oxide (NO) synthase activity. J. Neurosci. 14:134.
28. Danilov A.I., M. Andersson, N. Bavand, N.P. Wiklund, T. Olsson and L. Brundin. 2003. Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J. Neuroimmunol. 136:112.
29. Christen S., M. Schaper, J. Lykkesfeldt, C. Siegenthaler, Y.D. Bifrare, S. Banic, S.L. Leib and M.G. Tauber. 2001. Oxidative stress in brain during experimental bacterial meningitis: differential effects of alpha-phenyltert- butyl nitrone and N-acetylcysteine treatment. Free Radic. Biol. Med. 31:754.
30. Hauss-Wegrzyniak B., L.B. Willard, P. Del Soldato, G. Pepeu and G.L. Wenk. 1999. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Research 815:36.
31. Scali C., C. Prosperi, M.G. Vannucchi, G. Pepeu and F. Casamenti. 2000. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur. J. Neurosci. 12:1900.
32. Dimmeler S., J. Haendeler, M. Nehls and A.M. Zeiher. 1997. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp. Med. 185:601.
33. Fiorucci S., L. Santucci, G. Cirino, A. Mencarelli, L. Familiari, P.D. Soldato and A. Morelli. 2000. IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. J. Immunol. 165:5245.
34. Fiorucci S., A. Mencarelli, R. Mannucci, E. Distrutti, A. Morelli, P. Del Soldato and S. Moncada. 2002. NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function. FASEB J. 16:1645.
35. Kim Y.M., R.V. Talanian, J. Li and T.R. Billiar. 1998. Nitric oxide prevents IL-1 beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). J. Immunol. 161:4122.
36. Kolb H. and V. Kolb-Bachofen. 1998. Nitric oxide in autoimmune disease: cytotoxic or regulatory mediator? Immunol. Today 19:556.
37. Fiorucci S., A. Mencarelli, A. Meneguzzi, A. Lechi, A. Morelli, P. Del Soldato and P. Minuz. 2002. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide- induced tissue factor expression in vivo: role of nitric oxide. Circulation 106:3120.
38. Kanski J., M. Aksenova, A. Stoyanova and D.A. Butterfield. 2002. Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: sntructure-activity studies. J. Nutr. Biochem. 13:273.